Tango Therapeutics (TNGX) Competitors $5.69 +0.04 (+0.71%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$5.69 0.00 (0.00%) As of 07/3/2025 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNGX vs. TWST, VCEL, NAMS, DNLI, KNSA, RXRX, APGE, CGON, AGIO, and INDVShould you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include Twist Bioscience (TWST), Vericel (VCEL), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), CG Oncology (CGON), Agios Pharmaceuticals (AGIO), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry. Tango Therapeutics vs. Its Competitors Twist Bioscience Vericel NewAmsterdam Pharma Denali Therapeutics Kiniksa Pharmaceuticals International Recursion Pharmaceuticals Apogee Therapeutics CG Oncology Agios Pharmaceuticals Indivior Twist Bioscience (NASDAQ:TWST) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings. Is TWST or TNGX more profitable? Twist Bioscience has a net margin of -54.98% compared to Tango Therapeutics' net margin of -322.67%. Twist Bioscience's return on equity of -33.48% beat Tango Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-54.98% -33.48% -25.34% Tango Therapeutics -322.67%-62.75%-39.94% Which has stronger earnings & valuation, TWST or TNGX? Tango Therapeutics has lower revenue, but higher earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$312.97M7.30-$208.73M-$3.25-11.73Tango Therapeutics$42.07M14.66-$130.30M-$1.22-4.66 Which has more risk & volatility, TWST or TNGX? Twist Bioscience has a beta of 2.41, meaning that its stock price is 141% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Do analysts prefer TWST or TNGX? Twist Bioscience presently has a consensus price target of $50.40, suggesting a potential upside of 32.25%. Tango Therapeutics has a consensus price target of $12.20, suggesting a potential upside of 114.41%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of TWST or TNGX? 79.0% of Tango Therapeutics shares are held by institutional investors. 3.0% of Twist Bioscience shares are held by insiders. Comparatively, 7.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer TWST or TNGX? In the previous week, Tango Therapeutics had 2 more articles in the media than Twist Bioscience. MarketBeat recorded 5 mentions for Tango Therapeutics and 3 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.08 beat Tango Therapeutics' score of 0.49 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTango Therapeutics beats Twist Bioscience on 8 of the 15 factors compared between the two stocks. Get Tango Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNGX vs. The Competition Export to ExcelMetricTango TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$617.85M$2.92B$5.56B$9.05BDividend YieldN/A2.44%5.24%3.99%P/E RatioN/A8.2819.9620.26Price / Sales14.66283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book3.067.538.035.65Net Income-$130.30M-$55.14M$3.18B$249.15M7 Day Performance13.57%4.61%2.93%3.28%1 Month Performance33.57%0.90%1.72%3.95%1 Year Performance-33.53%5.40%34.39%20.98% Tango Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNGXTango Therapeutics1.9764 of 5 stars$5.69+0.7%$12.20+114.4%-33.5%$617.85M$42.07M0.0090Analyst RevisionTWSTTwist Bioscience4.4645 of 5 stars$36.79+2.4%$50.40+37.0%-21.4%$2.15B$312.97M-11.32990Positive NewsVCELVericel2.8341 of 5 stars$42.55+2.0%$61.14+43.7%-10.5%$2.10B$237.22M1,418.81300News CoveragePositive NewsNAMSNewAmsterdam Pharma2.2741 of 5 stars$18.11-2.5%$42.89+136.8%-0.8%$2.08B$45.56M-9.634Analyst UpgradeDNLIDenali Therapeutics4.6319 of 5 stars$13.99-0.8%$33.71+141.0%-30.5%$2.05B$330.53M-5.24430Positive NewsKNSAKiniksa Pharmaceuticals International3.2836 of 5 stars$27.67-1.3%$38.80+40.2%+43.9%$2.05B$423.24M-110.68220Analyst UpgradeRXRXRecursion Pharmaceuticals1.9157 of 5 stars$5.06+0.6%$7.00+38.3%-28.1%$2.04B$58.84M-2.86400Analyst ForecastAPGEApogee Therapeutics2.8711 of 5 stars$43.43+0.1%$94.60+117.8%+25.1%$2.00BN/A-12.0691News CoverageAnalyst ForecastInsider TradeHigh Trading VolumeCGONCG Oncology2.3486 of 5 stars$26.00+0.2%$58.67+125.6%-15.6%$1.98B$1.14M-17.2261AGIOAgios Pharmaceuticals4.0117 of 5 stars$33.26-0.6%$58.60+76.2%-15.5%$1.94B$36.50M2.96390Insider TradeINDVIndivior2.052 of 5 stars$14.74+5.7%$17.00+15.3%+6.5%$1.92B$1.19B-47.551,051News CoverageHigh Trading Volume Related Companies and Tools Related Companies TWST Competitors VCEL Competitors NAMS Competitors DNLI Competitors KNSA Competitors RXRX Competitors APGE Competitors CGON Competitors AGIO Competitors INDV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNGX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredGold buying hits 4-year highThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.